Drugs.com - New Drug Approvals

FDA Approves Atzumi (dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine

DURHAM, N.C., April 30, 2025 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions, and its corporate parent...

May 1, 2025 - 02:55
 0
FDA Approves Atzumi (dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine
DURHAM, N.C., April 30, 2025 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions, and its corporate parent...
Read More

Tags:

Previous Article

South of Gandy apartments sell for a major loss

Next Article

Meyer Jabara Hotels Continues Texas Expansion

Related Posts

FDA Approves Expanded Use of Soliris (eculizumab) for Pediatric Myasthenia Gravis, Bringing New Treatment Options for Children

FDA Approves Expanded Use of Soliris (eculizumab) for P...

Apr 26, 2025  0

FDA Approves an Updated Label for Tryvio (aprocitentan) Removing the REMS Requirement

FDA Approves an Updated Label for Tryvio (aprocitentan)...

Apr 26, 2025  0

FDA Approves Tremfya (guselkumab) for Adult Patients with Moderately to Severely Active Crohn’s Disease

FDA Approves Tremfya (guselkumab) for Adult Patients wi...

Apr 26, 2025  0